<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Previous studies showed that the assessment of promoter hypermethylation of a limited number of genes in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> biopsies may identify the majority of <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumors</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>This study aimed to assess the clinical usefulness of a panel of methylation biomarkers in stool DNA in the identification of <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumors</z:e>, using methylation-specific melting curve analysis (MS-<z:chebi fb="70" ids="34342">MCA</z:chebi>), a technique that simultaneously analyzes <z:hpo ids='HP_0000001'>all</z:hpo> <z:chebi fb="1" ids="16040">cytosine</z:chebi>-phosphate-<z:chebi fb="1" ids="16235">guanine</z:chebi> (CpG) residues within a promoter </plain></SENT>
<SENT sid="2" pm="."><plain>MATERIALS AND METHODS: The promoter methylation status of 4 tumor-related genes (RARB2, p16INK4a, MGMT, and APC) was analyzed in DNA stool samples and corresponding tissues in an initial set of 12 patients with newly diagnosed primary colorectal <z:mp ids='MP_0002038'>carcinomas</z:mp> and 20 patients with newly diagnosed colorectal <z:mpath ids='MPATH_270'>adenomas</z:mpath>, using methylation-specific polymerase chain reaction </plain></SENT>
<SENT sid="3" pm="."><plain>Results were replicated in a set of 82 patients (20 healthy subjects, 16 patients with <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e> (IBD), 20 patients with <z:mpath ids='MPATH_270'>adenomas</z:mpath>, and 26 patients with <z:mp ids='MP_0002038'>carcinomas</z:mp>), using MS-<z:chebi fb="70" ids="34342">MCA</z:chebi> analyses </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: In the initial set, &gt;or= 1 positive methylation marker was detected in the stools of 9 of 12 patients (75%) with <z:mp ids='MP_0002038'>carcinomas</z:mp> and 12 of 20 patients (60%) with <z:mpath ids='MPATH_270'>adenomas</z:mpath>, with no false-positive results </plain></SENT>
<SENT sid="5" pm="."><plain>Stool analyses missed 7 methylated lesions (25%) </plain></SENT>
<SENT sid="6" pm="."><plain>In the replication set, stool DNA testing detected 16 of 26 <z:mp ids='MP_0002038'>carcinomas</z:mp> (62%) and 8 of 20 <z:mpath ids='MPATH_270'>adenomas</z:mpath> (40%) </plain></SENT>
<SENT sid="7" pm="."><plain>The MS-<z:chebi fb="70" ids="34342">MCAs</z:chebi> missed 14 methylated <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> (37%) </plain></SENT>
<SENT sid="8" pm="."><plain>No aberrant methylation was evident in healthy subjects, but the RARB2 marker was positive in 2 of 15 stool samples (13%) of patients with IBD </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: Analysis via MS-<z:chebi fb="70" ids="34342">MCA</z:chebi> of a panel of methylation markers in stool DNA may offer a good alternative in the early, noninvasive detection of <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumors</z:e> </plain></SENT>
</text></document>